A subtype of breast cancer overexpresses HER2 receptors and is called HER2-positive (HER2+); HER2+ breast cancer accounts for 15–20% of all breast cancers and is associated with poor patient outcome and aggressive phenotype [3]. Here, ERBB2 is linked to breast carcinoma.